CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Novo Nordisk A/S - share repurchase programme

Neutral
AI Analysis

Summary

Novo Nordisk initiated a share repurchase programme on May 6, 2026, with a total authorization of DKK 15 billion over a 12-month period beginning February 4, 2026, in compliance with European Market Abuse Regulation.

Importance:2/10
Sentiment:
0.00
share repurchasecapital allocationshareholder return
Related Companies

Read the original article

Published by GlobeNewswire Pharma on July 6, 2026 10:16 AM

Read Original